Next Article in Journal
Kramecyne — A New Anti-inflammatory Compound Isolated from Krameria cytisoides
Next Article in Special Issue
Reaction Dynamics of Flavonoids and Carotenoids as Antioxidants
Previous Article in Journal
3D-QSAR Studies of Dihydropyrazole and Dihydropyrrole Derivatives as Inhibitors of Human Mitotic Kinesin Eg5 Based on Molecular Docking
Previous Article in Special Issue
Pressurized Hot Ethanol Extraction of Carotenoids from Carrot By-Products

Astaxanthin in Cardiovascular Health and Disease

by 1,2,3,*,† and 3,†
School of Medicine, The University of Queensland, Brisbane, Queensland, 4000, Australia
Department of Renal Medicine, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, 4029, Australia
The School of Human Movement Studies, The University of Queensland, St Lucia, Queensland, 4072, Australia
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Molecules 2012, 17(2), 2030-2048;
Received: 18 January 2012 / Revised: 13 February 2012 / Accepted: 13 February 2012 / Published: 20 February 2012
(This article belongs to the Special Issue Carotenoids)
Oxidative stress and inflammation are established processes contributing to cardiovascular disease caused by atherosclerosis. However, antioxidant therapies tested in cardiovascular disease such as vitamin E, C and β-carotene have proved unsuccessful at reducing cardiovascular events and mortality. Although these outcomes may reflect limitations in trial design, new, more potent antioxidant therapies are being pursued. Astaxanthin, a carotenoid found in microalgae, fungi, complex plants, seafood, flamingos and quail is one such agent. It has antioxidant and anti-inflammatory effects. Limited, short duration and small sample size studies have assessed the effects of astaxanthin on oxidative stress and inflammation biomarkers and have investigated bioavailability and safety. So far no significant adverse events have been observed and biomarkers of oxidative stress and inflammation are attenuated with astaxanthin supplementation. Experimental investigations in a range of species using a cardiac ischaemia-reperfusion model demonstrated cardiac muscle preservation when astaxanthin is administered either orally or intravenously prior to the induction of ischaemia. Human clinical cardiovascular studies using astaxanthin therapy have not yet been reported. On the basis of the promising results of experimental cardiovascular studies and the physicochemical and antioxidant properties and safety profile of astaxanthin, clinical trials should be undertaken. View Full-Text
Keywords: antioxidants; marine carotenoids; inflammation; oxidative stress; cardiovascular disease antioxidants; marine carotenoids; inflammation; oxidative stress; cardiovascular disease
Show Figures

Figure 1

MDPI and ACS Style

Fassett, R.G.; Coombes, J.S. Astaxanthin in Cardiovascular Health and Disease. Molecules 2012, 17, 2030-2048.

AMA Style

Fassett RG, Coombes JS. Astaxanthin in Cardiovascular Health and Disease. Molecules. 2012; 17(2):2030-2048.

Chicago/Turabian Style

Fassett, Robert G., and Jeff S. Coombes. 2012. "Astaxanthin in Cardiovascular Health and Disease" Molecules 17, no. 2: 2030-2048.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop